Uniqure NV at Stifel CNS Days (Virtual) Transcript
Great. Thanks very much, everybody, for continuing on here. It's my pleasure to be moderating a chat with the CEO of uniQure, Matt Kapusta. We'll probably talk most of the time about Huntington's, but maybe I can just turn it over to Matt briefly to give us a brief update on the AMT-130 study, cadence of readouts, as well as any other quick hits in the pipeline.
So, Matt, thank you again and looking forward to the discussion.
Yes, Paul, thank you very much for having us here in Stifel. We really appreciate being involved in the conference. So with respect to AMT-130, just to step back, we have our two active clinical trials that are currently ongoing. One is taking place in the United States as a Phase 1/2 and the other one is taking place in Europe as a Phase 1b/2.
They're both exploring two different doses, the same two different doses. And really the only difference is that the US study is a randomized, controlled, double-blinded study with a one-year blinding
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |